Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2018 - 2026)

Alnylam Pharmaceuticals has reported Cost of Revenue for 9 years, with the latest figure at $207.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 195.68% year-over-year to $207.5 million; the trailing twelve-month figure through Mar 2026 stood at $814.5 million (up 152.89% YoY), and the FY2025 full-year result was $677.2 million, up 120.93% from the prior year.
• Cost of Revenue for Q1 2026 stood at $207.5 million, down from $267.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $267.7 million in Q4 2025, with the low at $23.5 million in Q1 2022.
• Historically, Cost of Revenue has averaged $94.1 million across 5 years, with a median of $72.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cost of Revenue slipped 10.71% — and 2026, when it soared 195.68%.
• Alnylam Pharmaceuticals' Cost of Revenue stood at $46.2 million in 2022, then surged by 55.88% to $72.0 million in 2023, then soared by 42.62% to $102.6 million in 2024, then jumped by 160.81% to $267.7 million in 2025, then slipped by 22.49% to $207.5 million in 2026.
• The last three Cost of Revenue figures came in at $207.5 million (Q1 2026), $267.7 million (Q4 2025), and $197.2 million (Q3 2025), per Business Quant data.